Atopic dermatitis treatment sales will expand through 2035, with biologic therapy at 26% within the product segment and hospital pharmacies at 30% of the end user category in 2025. The market was valued at USD 16.8 billion in 2025 and is forecast to record an 11.7% CAGR between 2025 and 2035.